Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Aliskiren
Drug ID BADD_D00073
Description Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension.[A203624] It was developed by Speedel and Novartis and initially approved by the FDA in early 2007.[L14018] Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.[A203624]
Indications and Usage For the treatment of hypertension, to lower blood pressure.
Marketing Status Prescription
ATC Code C09XA02
DrugBank ID DB09026
KEGG ID D03208
MeSH ID C446481
PubChem ID 5493444
TTD Drug ID D03SVX
NDC Product Code 49884-425; 49884-424
Synonyms aliskiren | rasilez | Tekturna | CGP 060536B | CGP060536B | CGP-060536B | 2(S),4(S),5(S),7(S)-N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-(4-methoxy-3-(3-methoxypropoxy)phenyl)octanamid hemifumarate | SPP100
Chemical Information
Molecular Formula C30H53N3O6
CAS Registry Number 173334-57-1
SMILES CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Chest pain02.02.02.011; 08.01.08.002; 22.02.08.0030.006982%Not Available
Cholecystitis09.03.01.0010.002793%
Chronic obstructive pulmonary disease22.03.01.0070.004189%Not Available
Colon cancer07.21.01.001; 16.13.01.001--Not Available
Constipation07.02.02.001--
Coronary artery disease02.02.01.001; 24.04.04.0060.008378%Not Available
Cough22.02.03.0010.004189%
Death08.04.01.001--
Dehydration14.05.05.0010.006982%
Dermatitis23.03.04.002--Not Available
Diabetes mellitus05.06.01.001; 14.06.01.0010.008378%Not Available
Diarrhoea07.02.01.001--
Dizziness02.01.02.004; 17.02.05.003; 24.06.02.0070.006982%
Drug effect increased08.06.01.011--Not Available
Dyspepsia07.01.02.001--
Dyspnoea02.01.03.002; 22.02.01.0040.025135%
Dyspnoea at rest02.01.03.007; 22.02.01.0250.002793%Not Available
Epistaxis22.04.03.001; 24.07.01.005--
Erythema23.03.06.001--Not Available
Erythema multiforme10.01.03.015; 23.03.01.003--
Fatigue08.01.01.0020.009775%
Fluid overload02.05.04.004; 14.05.06.0010.002793%Not Available
Gastrooesophageal reflux disease07.02.02.0030.004189%
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Generalised tonic-clonic seizure17.12.01.002--Not Available
Glycosylated haemoglobin increased13.02.02.0050.008378%Not Available
Gout14.09.01.001; 15.01.06.0010.002793%Not Available
Haematocrit decreased13.01.05.001--Not Available
Haemoglobin decreased13.01.05.003--Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 6 Pages